Hyderabad-based drug maker Natco Pharma reported an 8.5 per cent rise in its consolidated net profit at Rs 43.98 crore for the year ended March 2009, compared with Rs 40.52 crore posted in the previous year.
Revenues were up to Rs 465 crore from Rs 364 crore in the same period, registering a growth of 28 per cent.
The company stated that the growth in profit was lower on account of expenses on Phase I clinical trials of its new chemical entity with multiple oncological indications.
